An Overview of Meningiomas

References

• Chamberlain MC . Meningiomas. In: Primary Central Nervous System Tumors: Pathogenesis and Therapy. NordenAD, ReardonDA, WenPCY ( Eds). Humana Press, NJ, USA, 355–375 (2011).
   Google Scholar
• Ostrom QT , GittlemanH, XuJet al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro-oncology18(Suppl. 5), v1–v75 (2016).
   PubMedGoogle Scholar
• Central Brain Tumor Registry of the United States (CBTRUS) , 2005. Primary brain tumors in the United States statistical report 1998–2002. www.cbtrus.org/reports/2005-2006/2006report.pdf.
   Google Scholar
• Hatch EE , LinetMS, ZhangJet al. Reproductive and hormonal factors and risk of brain tumors in adult females. Int. J. Cancer114(5), 797–805 (2005).
   PubMed Web of Science ®Google Scholar
• Wiemels J , WrenschM, ClausEB. Epidemiology and etiology of meningioma. J. Neurooncol.99(3), 307–314 (2010).
   PubMed Web of Science ®Google Scholar
• Rogers L , BaraniI, ChamberlainMCet al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. a RANO review. J. Neurosurg.122(1), 4–23 (2015).
   PubMed Web of Science ®Google Scholar
• Hashiba T , HashimotoN, IzumotoSet al. Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas. J. Neurosurg.110(4), 675–684 (2009).
   PubMed Web of Science ®Google Scholar
• Soon WC , FountainDM, KoczykKet al. Correlation of volumetric growth and histological grade in 50 meningiomas. Acta Neurochir.159(11), 2169–2177 (2017).
   PubMed Web of Science ®Google Scholar
• Fountain DM , SoonWC, MatysT, GuilfoyleMR, KirollosR, SantariusT. Volumetric growth rates of meningioma and its correlation with histological diagnosis and clinical outcome: a systematic review. Acta Neurochir.159(3), 435–445 (2017).
   PubMed Web of Science ®Google Scholar
• Wen PY , MacDonalDR, ReardonDAet al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol.28(11), 1963–1972 (2010).
   PubMed Web of Science ®Google Scholar
• Franz DN , BelousovaE, SparaganaSet al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open label extension of the randomised EXIST-1 study. Lancet Oncol.15(13), 1513–1520 (2014).
   PubMed Web of Science ®Google Scholar
• Watts J , BoxG, GalvinA, BrotchieP, TrostN, SutherlandT. Magnetic resonance imaging of meningiomas: a pictorial review. Insights Imaging5(1), 113–122 (2014).
   PubMedGoogle Scholar
• Rachinger W , StoeckleinVM, TerpolilliNAet al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J. Nuc. Med.56(3), 347–353 (2015).
   PubMed Web of Science ®Google Scholar
• Afshar-Oromieh A , WolfMB, KratochwilCet al. Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: initial results. Neuro-oncology17(2), 312–319 (2015).
   PubMed Web of Science ®Google Scholar
• Rutten I , CabayJ-E, WithofsNet al. PET/CT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: initial report. J. Nucl. Med.48(5), 720–725 (2007).
   PubMed Web of Science ®Google Scholar
• Bosnyak E , KamsonDO, GuastellaARet al. Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas. Neuro-oncology17(9), 1284–1292 (2015).
   PubMed Web of Science ®Google Scholar
• Harting I , HartmannM, BonsantoMM, SommerC, SartorK. Characterization of necrotic meningioma using diffusion MRI, perfusion MRI, and MR spectroscopy: case report and review of the literature. Neuroradiology46(3), 189–193 (2004).
   PubMed Web of Science ®Google Scholar
• Buhl R , NabaviA, WolffSet al. MR spectroscopy in patients with intracranial meningiomas. Neurol. Res.29(1), 43–46 (2007).
   PubMed Web of Science ®Google Scholar
• Menke JR , RaleighDR, GownAM, ThomasS, PerryA, TihanT. Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathologica130(3), 441–443 (2015).
   PubMed Web of Science ®Google Scholar
• Hsu DW , EfirdJT, Hedley-WhyteET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J. Neurosurg.86(1), 113–120 (1997).
   PubMed Web of Science ®Google Scholar
• Pravdenkova S , Al-MeftyO, SawyerJ, HusainM. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J. Neurosurg.105(2), 163–173 (2006).
   PubMed Web of Science ®Google Scholar
• Louis DN , PerryA, ReifenbergerGet al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica131(6), 803–820 (2016).
   PubMed Web of Science ®Google Scholar
• Vranic A , PopovicM, CörA, PrestorB, PizemJ. Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients. Neurosurgery67(4), 1124–1132 (2010).
   PubMed Web of Science ®Google Scholar
• Rouleau GA , MerelP, LutchmanMet al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature363(6429), 515–521 (1993).
   PubMed Web of Science ®Google Scholar
• Trofatter JA , MacCollinMM, RutterJLet al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell72(5), 791–800 (1993).
   PubMed Web of Science ®Google Scholar
• Brastianos PK , HorowitzPM, SantagataSet al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat. Genet.45(3), 285–289 (2013).
   PubMed Web of Science ®Google Scholar
• Choy W , KimW, NagasawaDet al. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg. Focus30(5), E6 (2011).
   PubMed Web of Science ®Google Scholar
• Abedalthagafi M , BiWL, AizerAAet al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro-oncology18(5), 649–655 (2016).
   PubMed Web of Science ®Google Scholar
• Clark VE , HarmancıAS, BaiHet al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat. Genet.48(10), 1253–1259 (2016).
   PubMed Web of Science ®Google Scholar
• Clark VE , Erson-OmayEZ, SerinAet al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science339(6123), 1077–1080 (2013).
   PubMed Web of Science ®Google Scholar
• Wellenreuther R , KrausJA, LenartzDet al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am. J. Pathol.146(4), 827–832 (1995).
   PubMed Web of Science ®Google Scholar
• Reuss DE , PiroRM, JonesDTWet al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol.125(3), 351–358 (2013).
   PubMed Web of Science ®Google Scholar
• Sahm F , BisselJ, KoelscheCet al. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol.126(5), 757–762 (2013).
   PubMed Web of Science ®Google Scholar
• Aizer AA , AbedalthagafiM, BiWLet al. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro-oncology18(2), 269–274 (2016).
   PubMed Web of Science ®Google Scholar
• Goutagny S , NaultJC, MalletM, HeninD, RossiJZ, KalamaridesM. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol.24(2), 184–189 (2014).
   PubMed Web of Science ®Google Scholar
• Sahm F , SchrimpfD, OlarAet al. TERT promoter mutations and risk of recurrence in meningioma. J. Natl Cancer Inst.108(5), djv377 (2016).
   PubMedGoogle Scholar
• Sahm F , SchrimpfD, StichelDet al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol.18(5), 682–694 (2017).
   PubMed Web of Science ®Google Scholar
• Olar A , WaniKM, WilsonCDet al. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol.133(3), 431–444 (2017).
   PubMed Web of Science ®Google Scholar
• Zada G , BaşkayaMK, ShahMV. Introduction: surgical management of skull base meningiomas. Neurosurg. Focus43(Video Suppl. 2), Intro (2017).
   Google Scholar
• Mirimanoff RO , DosoretzDE, LinggoodRM, OjemannRG, MartuzaRL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J. Neurosurg.62(1), 18–24 (1985).
   PubMed Web of Science ®Google Scholar
• Simpson D . The recurrence of intracranial meningiomas after surgical treatment. J. Neurol. Neurosurg. Psych.20(1), 22–39 (1957).
   PubMed Web of Science ®Google Scholar
• Sun SQ , HawasliAH, HuangJ, ChicoineMR, KimAH. An evidence-based treatment algorithm for the management of WHO grade II and III meningiomas. Neurosurg. Focus38(3), E3 (2015).
   PubMed Web of Science ®Google Scholar
• Oya S , KawaiK, NakatomiH, SaitoN. Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO grade I meningiomas. J. Neurosurg.117(1), 121–128 (2012).
   PubMed Web of Science ®Google Scholar
• Walcott BP , NahedBV, BrastianosPK, LoefflerJS. Radiation treatment for WHO grade II and III meningiomas. Front. Oncol.3, 227 (2013).
   PubMedGoogle Scholar
• Nicolato A , ForoniR, PellegrinoMet al. Gamma knife radiosurgery in meningiomas of the posterior fossa. Experience with 62 treated lesions. Minim. Invasive Neurosurg. 44(4), 211–217 (2001).
   PubMedGoogle Scholar
• Sheehan JP , Cohen-InbarO, RuangkanchanasetrRet al. Post-radiosurgical edema associated with parasagittal and parafalcine meningiomas: a multicenter study. J. Neurooncol.125(2), 317–324 (2015).
   PubMed Web of Science ®Google Scholar
• Sheehan JP , StarkeRM, KanoHet al. Gamma Knife radiosurgery for posterior fossa meningiomas: a multicenter study. J. Neurosurg.122(6), 1479–1489 (2015).
   PubMed Web of Science ®Google Scholar
• Pollock BE , StaffordSL, UtterA, GianniniC, SchreinerSA. Stereotactic radiosurgery provides equivalent tumor control to Simpson grade 1 resection for patients with small- to medium-size meningiomas. Int. J. Radiat. Oncol. Biol. Phys.55(4), 1000–1005 (2003).
   PubMed Web of Science ®Google Scholar
• Pollock BE , StaffordSL, LinkMJ, GarcesYI, FooteRL. Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomas: treatment results on the basis of a 22-year experience. Cancer118(4), 1048–1054 (2012).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick JP , SoltysSG, LoSS, BealK, ShrieveDC, BrownPD. The radiosurgery fractionation quandary: single fraction or hypofractionation?Neuro-oncology19(Suppl. 2), ii38–ii49 (2017).
   PubMedGoogle Scholar
• Bria C , WegnerRE, ClumpDAet al. Fractionated stereotactic radiosurgery for the treatment of meningiomas. J. Cancer Res. Ther.7(1), 52–57 (2011).
   PubMed Web of Science ®Google Scholar
• Onodera S , AoyamaH, KatohNet al. Long-term outcomes of fractionated stereotactic radiotherapy for intracranial skull base benign meningiomas in single institution. Jpn J. Clin. Oncol.41(4), 462–468 (2011).
   PubMed Web of Science ®Google Scholar
• Aghi MK , CarterBS, CosgroveGRet al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery64(1), 56–60 (2009).
   PubMed Web of Science ®Google Scholar
• Komotar RJ , IorgulescuJB, RaperDMSet al. The role of radiotherapy following gross-total resection of atypical meningiomas. J. Neurosurg.117(4), 679–686 (2012).
   PubMed Web of Science ®Google Scholar
• Dziuk TW , WooS, ButlerEBet al. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J. Neurooncol.37(2), 177–188 (1998).
   PubMed Web of Science ®Google Scholar
• Rogers L , ZhangP, VogelbaumMAet al. Low-risk meningioma: initial outcomes from NRG oncology/RTOG 0539. Int. J. Radiat. Oncol. Biol. Phys.96(5), 939–440 (2016).
   Web of Science ®Google Scholar
• Rogers L , ZhangP, VogelbaumMAet al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J. Neurosurg.5, 1–13 (2017).
   Google Scholar
• Jenkinson MD , WeberDC, HaylockBJ, MallucciCL, ZakariaR, JavadpourM. Radiotherapy versus observation following surgical resection of atypical meningioma (the ROAM trial). Neuro-oncology16(11), 1560–1561 (2014).
   PubMed Web of Science ®Google Scholar
• Rogers L , ZhangP, VogelbaumMet al. MNGI-08. High-risk meningioma: initial outcomes from NRG ONCOLOGY/RTOG-0539. Neuro-oncology19(Suppl. 6), vi133 (2017).
   Google Scholar
• El-Khatib M , Majdoub ElF, HoevelsMet al. Stereotactic LINAC radiosurgery for incompletely resected or recurrent atypical and anaplastic meningiomas. Acta Neurochirurgica153(9), 1761–1767 (2011).
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines: central nervous system cancers . http://nccn.org/.
   Google Scholar
• Goldbrunner R , MinnitiG, PreusserMet al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol.17(9), e383–e391 (2016).
   PubMed Web of Science ®Google Scholar
• Karsy M , GuanJ, CohenA, ColmanH, JensenRL. Medical management of meningiomas: current status, failed treatments, and promising horizons. Neurosurg. Clin. N. Am.27(2), 249–260 (2016).
   PubMed Web of Science ®Google Scholar
• Kaley T , BaraniI, ChamberlainMCet al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-oncology16(6), 829–840 (2014).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC , JohnstonSK. Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J. Neurooncol.104(3), 765–771 (2011).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC . Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J. Neurooncol.107(2), 315–321 (2012).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC , Tsao-WeiDD, GroshenS. Temozolomide for treatment-resistant recurrent meningioma. Neurology62(7), 1210–1212 (2004).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC , Tsao-WeiDD, GroshenS. Salvage chemotherapy with CPT-11 for recurrent meningioma. J. Neurooncol.78(3), 271–276 (2006).
   PubMed Web of Science ®Google Scholar
• Koper JW , ZwarthoffEC, HagemeijerAet al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur. J. Cancer27(4), 416–419 (1991).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC , GlantzMJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer113(8), 2146–2151 (2008).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC . IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. CNS Oncol.2(3), 227–235 (2013).
   PubMedGoogle Scholar
• Le Rhun E , TaillibertS, ChamberlainMC. Systemic therapy for recurrent meningioma. Expert Rev. Neurotherapeutics16(8), 889–901 (2016).
   PubMed Web of Science ®Google Scholar
• Kaley TJ , WenP, SchiffDet al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-oncology17(1), 116–121 (2015).
   PubMed Web of Science ®Google Scholar
• Raizer JJ , GrimmSA, RademakerAet al. A Phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J. Neurooncol.117(1), 93–101 (2014).
   PubMed Web of Science ®Google Scholar
• Grimm S , KumthekarP, ChamberlainMCet al. MNGO-04 Phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. Neuro-oncology17(Suppl. 5), v130 (2015).
   Google Scholar
• Furtner J , SchöpfV, SeystahlKet al. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-oncology18(3), 401–407 (2016).
   PubMed Web of Science ®Google Scholar
• Norden AD , RaizerJJ, AbreyLEet al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J. Neurooncol.96(2), 211–217 (2009).
   PubMed Web of Science ®Google Scholar
• Wen PY , YungWKA, LambornKRet al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-oncology11(6), 853–860 (2009).
   PubMed Web of Science ®Google Scholar
• Ji Y , RankinC, GrunbergSet al. Double-blind Phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J. Clin. Oncol.33(34), 4093–4098 (2015).
   PubMed Web of Science ®Google Scholar
• Norden AD , LigonKL, HammondSNet al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology84(3), 280–286 (2015).
   PubMed Web of Science ®Google Scholar
• Simó M , ArgyriouAA, MaciàMet al. Recurrent high-grade meningioma: a Phase II trial with somatostatin analogue therapy. Cancer Chemother. Pharmacol.73(5), 919–923 (2014).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC , GlantzMJ, FadulCE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology69(10), 969–973 (2007).
   PubMed Web of Science ®Google Scholar
• Marincek N , RadojewskiP, DumontRAet al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a Phase II clinical trial. J. Nuc. Med.56(2), 171–176 (2015).
   PubMed Web of Science ®Google Scholar
• Graillon T , RomanoD, DefillesCet al. Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro. Oncotarget8(33), 55361–55373 (2017).
   PubMedGoogle Scholar
• Graillon T , DefillesC, MohamedAet al. Combined treatment by octreotide and everolimus: octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. J. Neurooncol.124(1), 33–43 (2015).
   PubMed Web of Science ®Google Scholar
• Wu S , GavrilovecI, La Fuente DeMI, KreislT, KaleyT. ACTR-43. Pilot study of optune (NOVOTTF-100A) for recurrent atypical and anaplastic meningioma. Neuro-oncology18(Suppl. 6), vi11–vi11 (2016).
   Google Scholar
• Eisele SC , WenPY, LeeEQ. Assessment of brain tumor response: RANO and its offspring. Curr. Treat. Options Oncol.17(7), 35 (2016).
   PubMed Web of Science ®Google Scholar